## **News Releases**



**Advanced Search** 

#### APR 26, 2023

Inhibrx Initiates a Registration-Enabling Trial of INBRX-101 in AATD and Announces Lift of Partial Clinical Hold on INBRX-109 DR5 Agonist Trials

### MAR 6, 2023

Inhibrx Reports Fourth Quarter and Fiscal Year 2022 Financial Results

# **JAN 4, 2023**

NorthStar Medical Radioisotopes and Inhibrx Enter into Collaboration Agreement for the Development and Production of Radiopharmaceutical Candidates

### NOV 18, 2022

Inhibrx Announces Participation in Upcoming Investor Conference

## NOV 16, 2022

Inhibrx Announces Updated Efficacy and Safety Data from the Expansion Cohorts in the Phase 1 Trial of INBRX-109 for the Treatment of Chondrosarcoma



